Extended Data Fig. 5: Observed clinical responses are associated with number of neoantigens included in the PTCV, but not known biomarkers of pembrolizumab response. | Nature Medicine

Extended Data Fig. 5: Observed clinical responses are associated with number of neoantigens included in the PTCV, but not known biomarkers of pembrolizumab response.

From: Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial

Extended Data Fig. 5

a, Responses stratified by tumor mutational burden (TMB). b, Biomarkers of the T-cell inflamed gene expression profile (GEP) are evaluated at pre-treatment between available non-responders (SD/PD; n = 23) and responders (CR/PR; n = 11) RNA sequencing data (tumor biopsy). c, Association between clinical responses and the number of neoantigens included in the PTCV. SD/PD (n = 23) and CR/PR (n = 11) subjects were evaluated. Graphs indicate mean ± standard error of the mean (SEM) of data from individual subjects (circles). Data are presented as mean ± SEM. Significance was evaluated by a two-tailed (a, c), one-tailed (b), Mann-Whitney statistical analysis.

Back to article page